Rgenix Inc. (New York, N.Y.) reported preliminary data from a Phase Ia/Ib trial showing that oral RGX-104 led to 4 cases of stable disease among 12 evaluable patients with advanced solid malignancies and lymphoma. To read the full article, please click here.
Month: November 2017
How Rgenix’s Liver X Agonist Could Help Overcome Checkpoint Resistance in Cancer. To read the full article, please click here.